or Try an Advanced Search...

    Technical Analysis for RKV - Rakovina Therapeutics Inc

    Grade Last Price % Change Price Change
    F 0.055 -8.33% -0.005
    RKV closed down 8.33 percent on Thursday, November 21, 2024, on 3.15 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: Nov 25
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical RKV trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish 0.00%
    Expansion Breakdown Bearish Swing Setup 0.00%
    Volume Surge Other 0.00%
    Wide Range Bar Range Expansion 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Stochastic Reached Oversold Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Below Lower BB Weakness 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Older End-of-Day Signals for RKV ...

       Recent Intraday Alerts

    Alert Time
    Down 2 ATRs about 15 hours ago
    Down 1 ATR about 17 hours ago
    Jack-in-the-Box Bearish Entry about 17 hours ago
    Fell Below Previous Day's Low about 17 hours ago
    Down 5% about 17 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    RKV Chart by TradingView
    Basic chart:

    Profile

    Rakovina Therapeutics, Inc., formerly Vincero Capital Corp., is a Canada-based company, which is engaged in developing cancer treatments based on DNA-damage response technologies. The Company’s lead product candidate is kt-2000 Next Generation PARP-inhibitors. Its pipeline includes kt-3000 Dual Action DDR-inhibitors and kt-4000 DNA Damaging DDR-inhibitors. Its kt-2000 series is a patented class of highly potent, oral inhibitors of poly (ADP-ribose) polymerase (PARP). Its kt-3000 drug candidates selectively inhibit secondary DDR pathways associated with treatment resistance and PARP. kt-4000 drug candidates release a potent DNA-damaging agent, while also inhibiting DDR to selectively kill cancer cells.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Cancer Biology Catalysts

    Is RKV a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 0.135
    52 Week Low 0.005
    Average Volume 83,270
    200-Day Moving Average 0.089
    50-Day Moving Average 0.084
    20-Day Moving Average 0.077
    10-Day Moving Average 0.074
    Average True Range 0.006
    RSI (14) 21.88
    ADX 39.55
    +DI 7.197
    -DI 61.869
    Chandelier Exit (Long, 3 ATRs) 0.063
    Chandelier Exit (Short, 3 ATRs) 0.062
    Upper Bollinger Bands 0.091
    Lower Bollinger Band 0.062
    Percent B (%b) -0.25
    BandWidth 38.021
    MACD Line -0.005
    MACD Signal Line -0.003
    MACD Histogram -0.0022
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.078
    Resistance 3 (R3) 0.077 0.068 0.074
    Resistance 2 (R2) 0.068 0.063 0.069 0.072
    Resistance 1 (R1) 0.062 0.059 0.058 0.063 0.071
    Pivot Point 0.053 0.053 0.051 0.054 0.053
    Support 1 (S1) 0.047 0.048 0.043 0.048 0.039
    Support 2 (S2) 0.038 0.044 0.039 0.038
    Support 3 (S3) 0.032 0.038 0.036
    Support 4 (S4) 0.033